Ureaplasma urealyticum colonization and relationship to chronic pulmonary disease in premature newborn infants younger than 32 weeks gestation;Colonisation par ureaplasma urealyticum et maladie pulmonaire chronique chez les nouvea-nés prématurés de moins de 32 semaines de gestation

Archives de Pediatrie

Volumn 8, Issue 1, 2001, Pages 39-46

  Galetto Lacour, A ^a   Zamora, S ^a   Bertrand, R ^a   Brighi Perret, L ^a   Auckenthaler, R ^b   Berner, M ^a   Suter, S ^a  

^a Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^b Lab Central de Bacteriologie   (Switzerland)

Author keywords

Bronchopulmonary dysplasia; Infant, low birth weight; Lung diseases; Ureaplasma urealyticum

Indexed keywords

CORTICOSTEROID; ERYTHROMYCIN; INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; BIRTH WEIGHT; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FUNGUS IDENTIFICATION; GENITAL TRACT INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; NASOPHARYNX; NEWBORN; NEWBORN DISEASE; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRACHEOBRONCHIAL TOILET; UREAPLASMA UREALYTICUM;

EID: 0035150792     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)00164-0     Document Type: Article

References (28)

1. Ureaplasma urealyticum intrauterine infection: Role in prematurity and disease in newborns
2. Risk factors for chronic lung disease in the surfactant era: A North Carolina population-based study of very low-birth weight infants
3. Bronchopulmonary dysplasia: Then and now
4. Urea-plasma urealyticum and chronic lung disease of prematurity: Critical appraisal of the literature on causation
5. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: Results of a metaanalysis
6. Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low-birth weight infants
7. Genital mycoplasmas in preterm infants: Prevalence and clinical significance
8. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants
9. Is chronic lung disease in low-birth weight infants preventable ? A survey of eight centers
10. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia
11. Ureaplasma urealyticum tracheal colonization and respiratory disease in newborns
12. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population
13. Ureaplasma urealyticum and chronic lung disease in very low-birth weight infants during the exogenous surfactant era
14. Role of Ureaplasma urealyticum in lung disease of prematurity
15. Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia
16. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin-6 in tracheal aspirates of preterm infants
17. Induction of neutrophil chemoattractant cytokines by Mycoplasma hominis in alveolar type II cells
18. Ureaplasma urealyticum in a neonatal intensive care population
19. Neonatal Ureaplasma urealyticum colonization and chronic lung disease
20. Ureaplasma urealyticum and chronic lung disease
21. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents
22. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922
23. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis
24. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants
25. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates
26. QT long et arrêt circulatoire après une injection d'érythromycine chez un nouveau-né
27. Cardiac toxicity associated with intravenous erythromycin lactobionate: Two case reports and a review of the literature
28. Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants